Natera and AFT Launch Phase III Trial for MRD-Guided Breast Cancer…

Event summary

AFT-70 NAVIGATE is a global, randomized Phase III trial evaluating Genentech’s oral selective estrogen receptor degrader (SERD) with Natera’s Signatera™ MRD-guided CDK4/6 inhibitor therapy in breast cancer.
The trial aims to enroll over 2,000 patients with stage II-III ER-positive/HER2-negative breast cancer across 200 sites.
Patients will be randomly assigned to either standard-of-care endocrine therapy plus upfront CDK4/6 inhibition or giredestrant monotherapy with CDK4/6 inhibition added only if Signatera becomes positive.
The primary endpoint is non-inferiority in 4-year distant recurrence-free survival.

The big picture

The AFT-70 NAVIGATE trial represents a significant step in personalized cancer treatment, leveraging molecular residual disease (MRD) monitoring to tailor therapy. This approach aims to reduce unnecessary toxicity while maintaining treatment efficacy, aligning with broader trends in precision oncology. The collaboration between AFT, Natera, and Genentech underscores the growing emphasis on integrating advanced diagnostics with targeted therapies to improve patient outcomes.

What we're watching

Trial Execution: The pace at which the trial enrolls 2,000 patients will determine its timeline and potential impact on treatment protocols.
Regulatory Approval: Whether the results of the trial will support the use of Signatera and giredestrant in clinical practice.
Market Adoption: How the outcomes will influence the adoption of MRD-guided treatment strategies in breast cancer care.